Cite
HARVARD Citation
Baruch, A. et al. (2017). A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clinical cardiology. 40 (7), pp. 503-511. [Online].